Scot JD - Treace Medical Chief Secretary
| TMCI Stock | USD 8.29 0.46 5.87% |
Executive
Scot JD is Chief Secretary of Treace Medical Concepts
| Age | 49 |
| Address | 100 Palmetto Park Place, Ponte Vedra, FL, United States, 32081 |
| Phone | 904 373 5940 |
| Web | https://www.treace.com |
Treace Medical Management Efficiency
The company has return on total asset (ROA) of (0.1713) % which means that it has lost $0.1713 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5069) %, meaning that it created substantial loss on money invested by shareholders. Treace Medical's management efficiency ratios could be used to measure how well Treace Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.23. The current Return On Capital Employed is estimated to decrease to -0.26. As of now, Treace Medical's Non Current Assets Total are increasing as compared to previous years. The Treace Medical's current Non Currrent Assets Other is estimated to increase to about 176.3 K, while Total Assets are projected to decrease to under 137.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dylan John | Neuropace | N/A | |
| Steve Kachelmeyer | Iradimed Co | N/A | |
| Stephen Deitsch | Paragon 28 | 52 | |
| Daniel JD | Orthopediatrics Corp | 54 | |
| Hans Kestler | Paragon 28 | N/A | |
| Jrme Erath | Pulmonx Corp | N/A | |
| Mehul Joshi | Pulmonx Corp | 63 | |
| John Ferrell | CONMED | 56 | |
| David Lehman | Pulmonx Corp | 63 | |
| Brent Lalomia | CONMED | 49 | |
| Irina Ridley | Neuropace | 38 | |
| Scott Gaines | Rxsight | N/A | |
| Matthew III | LivaNova PLC | N/A | |
| Rosalyn dIncelli | Establishment Labs Holdings | N/A | |
| Neeta Toprani | Establishment Labs Holdings | N/A | |
| Caroline Vaughn | Rxsight | N/A | |
| Matthew Brinckman | Paragon 28 | N/A | |
| Brenton Taylor | Sight Sciences | 43 | |
| John Shumaker | Paragon 28 | N/A | |
| Matthew Jarboe | Paragon 28 | 41 | |
| Sarah Oliker | CONMED | 43 | |
Management Performance
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.17 |
Treace Medical Concepts Leadership Team
Elected by the shareholders, the Treace Medical's board of directors comprises two types of representatives: Treace Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Treace. The board's role is to monitor Treace Medical's management team and ensure that shareholders' interests are well served. Treace Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Treace Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shana Zink, Senior Reimbursement | ||
| Julie Dewey, Chief Officer | ||
| Scot JD, Chief Secretary | ||
| Thomas Timbie, Independent Director | ||
| John Treace, Founder CEO | ||
| Sean Scanlan, Chief Officer | ||
| Nathan Minnich, Senior Marketing | ||
| Scot Elder, Chief Secretary | ||
| Rachel Osbeck, Senior Affairs | ||
| Mark CPA, Chief Officer | ||
| Taylor Erickson, Chief Officer | ||
| Aaron Berutti, Senior Sales | ||
| Jaime Frias, Chief Officer | ||
| Daniel Owens, Chief Officer | ||
| Terry Lubben, Senior Operations |
Treace Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Treace Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 475.11 M | ||||
| Shares Outstanding | 62.3 M | ||||
| Shares Owned By Insiders | 24.82 % | ||||
| Shares Owned By Institutions | 64.34 % | ||||
| Number Of Shares Shorted | 4.94 M | ||||
| Price To Book | 4.65 X |
Currently Active Assets on Macroaxis
When determining whether Treace Medical Concepts offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Treace Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Treace Medical Concepts Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Treace Medical Concepts Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Treace Medical Concepts. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Treace Medical. If investors know Treace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Treace Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 3.274 | Quarterly Revenue Growth 0.106 | Return On Assets (0.17) | Return On Equity (0.51) |
The market value of Treace Medical Concepts is measured differently than its book value, which is the value of Treace that is recorded on the company's balance sheet. Investors also form their own opinion of Treace Medical's value that differs from its market value or its book value, called intrinsic value, which is Treace Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Treace Medical's market value can be influenced by many factors that don't directly affect Treace Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Treace Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Treace Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Treace Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.